A Clinical Study on Neoadjuvant Treatment of Resectable Head and Neck Squamous Carcinoma With Immune-targeted Therapy and Lysogenic HSV Virus

StatusWithdrawn
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status changed: Recruiting → Withdrawn Sponsor's reason: The study was withdrawn prior to participant enrollment due to administrative and protocol optimization considerations. Show 4 more changesShow less
    • Enrollment target: estimated 21 to confirmed 0
    • Eligibility criteria expanded, about 28 words
    • Site details revised
    • Publications: details revised at 12 of 12 entries
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
Evaluation of the safety and tolerability of immune-targeted therapy combined with neoadjuvant therapy with lysogenic HSV virus for patients with surgically resectable squamous carcinoma of the head and neck.
Trial Details
NCT Number NCT06741982
Lead Sponsor West China Hospital
Conditions
(from sponsor)		 HNSCC, Lysogenic HSV Virus, Neoadjuvant Therapy, Immunotherapy, Targeted Therapy
Related terms Squamous Cell Carcinoma of Head and Neck
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov